By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel consensus is bearish on HIMS, citing growth deceleration, persistent operating losses, and regulatory risks (FTC lawsuit and potential FDA restrictions on GLP-1 compounding) that could further compress margins and delay profitability.
Risk: Growth deceleration and regulatory risks (FTC lawsuit and potential FDA restrictions on GLP-1 compounding) that could further compress margins and delay profitability.
Opportunity: None identified
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Hims & Hers Health (NYSE: HIMS) has been a hot growth stock to own in recent years. In 2024, it surged by 172%, and in 2025, it finished the year up 34%. But it's been struggling of late and is down significantly from its highs.
Recently, there's also been troubling news with the Federal Trade Commission (FTC) alleging that the telehealth company shared customer health information without consent. Things appear to be going from bad to worse for Hims & Hers Health. Is now the time to dump the stock, or could it be a good time to buy while its value is so low?
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
The FTC claims that Hims & Hers shared customer information without their consent on third-party platforms. However, Hims & Hers Health challenges the accusations, calling them "baseless" and noting that its privacy policy outlines how customer information is handled and managed.
While Hims & Hers stock initially fell when the news came out, the stock has gone on to recover since then. The privacy issues are concerning, but it's debatable how much of an impact they may have on the business or its long-term growth prospects. Sharing data, especially in an increasingly digital world, is something many companies struggle to strike a healthy balance on.
Privacy issues may have caused a momentary dip for the healthcare stock, but broader problems with the company's overall growth have been weighing it down for much longer. While the telehealth company has been expanding into new markets, its growth rate has been volatile and cratered to 4% recently.
The company has also incurred an operating loss totaling $31 million over the trailing 12 months. Its aggressive growth strategy has made it a hot stock to own in the past, but it can make for a highly volatile investment overall. While Hims may continue to pursue other opportunities to grow its business, investors will want to see that it can do so in a profitable way.
Without some greater predictability and stability in the company's overall earnings and growth, I'd avoid the stock. At around $7 billion in market cap, its valuation still isn't all that light as it trades at close to 60 times its estimated future earnings (based on analyst expectations).
Hims & Hers stock may be down significantly from its high, but it could still have plenty of room to fall even lower.
Before you buy stock in Hims & Hers Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $386,727! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,232,139!
Now, it’s worth noting Stock Advisor’s total average return is 906% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of August 3, 2026. *
David Jagielski, CPA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"Regulatory noise is manageable, but HIMS must prove it can grow profitably above 20% or the 60x multiple will compress sharply."
The FTC lawsuit over unauthorized sharing of sensitive health data is a serious regulatory and reputational risk for HIMS, especially given telehealth's reliance on trust. The article correctly flags slowing growth (only 4% in the latest quarter) and persistent operating losses ($31M TTM) at a still-rich ~60x forward P/E on a $7B market cap. However, it glosses over HIMS's successful GLP-1 weight-loss expansion, which has driven subscriber adds and could re-accelerate revenue if compounded with new categories. Privacy suits often settle with modest fines; the bigger question is whether the company can convert growth into sustainable profitability before the valuation rerates lower.
If the FTC case uncovers systemic HIPAA-level violations or triggers class-action suits and state AG actions, customer churn could spike far beyond the article's 'momentary dip,' collapsing the growth narrative and forcing a dilutive equity raise at depressed multiples.
"HIMS's current 60x forward P/E multiple is unsustainable given the company's recent 4% growth rate and failure to generate consistent operating income."
The article fixates on the FTC privacy headline, but the real structural issue is the 4% growth deceleration. HIMS is currently priced as a hyper-growth disruptor, yet its recent performance suggests it is transitioning into a commoditized telehealth provider. Trading at ~60x forward earnings, the stock lacks the margin of safety required for a company whose customer acquisition costs are rising while revenue expansion stalls. The FTC lawsuit is merely a distraction from the fundamental problem: the company has failed to prove it can scale profitably without burning cash. Until we see a re-acceleration in top-line growth or a clear path to sustained GAAP profitability, the valuation remains disconnected from reality.
If HIMS successfully pivots its GLP-1 weight-loss drug strategy and achieves operating leverage, the current 'stagnation' could be a temporary trough before a massive margin expansion cycle.
"HIMS trades at 60x forward P/E on 4% growth with trailing operating losses—a valuation that demands either immediate re-acceleration or a significant markdown, and the FTC case is a distraction from the real problem: the business model isn't yet profitable at scale."
The article conflates three separate issues—FTC litigation, 4% growth, and 60x forward P/E—without distinguishing their severity or timeline. The FTC case is real but unresolved; settlement risk exists but isn't quantified. More material: HIMS posted $31M operating loss trailing-twelve-months while trading at 60x forward earnings on 4% growth. That's not cheap; it's broken. However, the article omits HIMS's path to profitability, customer acquisition costs, or whether the 4% reflects a trough or structural deceleration. Telehealth reimbursement trends and competitive positioning (vs. Amazon Pharmacy, GoodRx) are absent. The valuation alone doesn't tell us if this is a value trap or a temporary markdown.
HIMS could be a classic growth-to-value transition: if it reaches 15–20% growth within 2–3 quarters while margins expand toward industry norms (15–20% EBITDA), a 60x multiple compresses to 25–30x and the stock doubles from here despite the FTC noise.
"Valuation hinges on aggressive growth that may not materialize, so any miss or tougher FTC outcome could trigger significant downside."
Hims & Hers Health faces a regulatory cloud from the FTC case, but the bigger risk is growth deceleration and profitability. A 4% recent growth rate and trailing $31 million operating loss imply the core model is not yet cash-flow positive at scale, while the stock trades near 60x forward earnings based on optimistic growth assumptions. A settlement or narrower enforcement could limit downside risk, yet valuation already prices in aggressive expansion and margin improvement that may not materialize quickly. Missing context includes FTC case specifics and penalties, the revenue mix (subscription versus services), customer retention dynamics, and whether cost discipline can unlock margin expansion in 2026-28. Also watch competitive pressure and data-privacy costs for insurers and platforms.
But the FTC case could prove to be overblown if a limited settlement emerges, turning into a short-term stumble rather than a structural headwind. If growth re-accelerates and cost discipline takes hold, the stock could re-rate, especially with a favorable data-privacy framework in place.
"FTC discovery risk directly amplifies the growth deceleration Claude treats as separable."
Claude correctly separates timelines but underweights second-order FTC risk: a prolonged discovery phase could unearth ad-targeting practices that trigger state AG suits and force HIMS to rewrite its entire GLP-1 customer-acquisition funnel. That would spike CAC further precisely when 4% growth already signals saturation, collapsing the 'temporary trough' narrative before any margin expansion materializes.
"The existential risk to Hims is not FTC privacy litigation but potential FDA regulatory shifts regarding the legality of their GLP-1 compounding business model."
Grok and Claude are missing the supply-side reality: Hims isn't just a platform; it's a compounder. The FTC risk is secondary to the regulatory vulnerability of their GLP-1 compounding business. If the FDA deems the current shortage-driven compounding model 'non-essential' or restricts access, the 4% growth isn't a trough—it's the ceiling. We are debating data privacy while ignoring the existential threat that their primary revenue engine could be legally throttled by shifting FDA enforcement priorities.
"FDA compounding risk is material but not existential; the trap is margin compression if HIMS must replace high-margin GLP-1 revenue with lower-margin alternatives while growth stalls."
Gemini's FDA compounding threat is underexplored but overstated as 'existential.' GLP-1 compounding fills a real shortage gap; FDA restriction would hurt HIMS but wouldn't eliminate the business—they'd pivot to brand-name drugs or other categories. The real issue: if compounding revenue collapses, HIMS loses its highest-margin segment precisely when 4% growth already signals core telehealth saturation. That's a margin compression trap, not a ceiling.
"Settlement won't fix profitability; the real test is whether GLP-1 revenue can generate sustained operating leverage, otherwise the 60x multiple is a bet on an unrealisable margin expansion."
Grok's focus on second-order FTC risk is valid, but the panel is underestimating the compliance costs and CAC implications. Even with a limited settlement, HIMS would need meaningful operating leverage to justify a 60x forward multiple; 4% growth and a $31M trailing loss imply several quarters of stabilization and cost discipline before margins recover. A regulatory shift on compounding could compress revenue quality, not just growth, delaying any re-rating.
The panel consensus is bearish on HIMS, citing growth deceleration, persistent operating losses, and regulatory risks (FTC lawsuit and potential FDA restrictions on GLP-1 compounding) that could further compress margins and delay profitability.
None identified
Growth deceleration and regulatory risks (FTC lawsuit and potential FDA restrictions on GLP-1 compounding) that could further compress margins and delay profitability.